39 completed, 13 terminated, 4 active not recruiting, 4 recruiting. 51 Phase 2, 7 Phase 3, 5 Phase 1, 1 Phase 4.
Follow AIO-Studien-gGmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden Tislelizumab, Tislelizumab Combined With Chemotherapy, Pembrolizumab - Non-small Cell Lung Cancer Metastatic | Phase 3 | Not yet recruiting | AIO-Studien-gGmbH | 230 | 2026-10-30 | 2026-10-26 |
| Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status Tarlatamab - Small-cell Lung Cancer | Phase 2 | Recruiting | AIO-Studien-gGmbH | 57 | 2025-01-01 | 2026-10-26 |
| Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome data collection - Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx | Recruiting | AIO-Studien-gGmbH | 120 | 2024-11-07 | 2024-11-13 | |
| AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT Minimal documentation, Extended documentation - Advanced Solid Tumor | Recruiting | AIO-Studien-gGmbH | 3000 | 2022-12-08 | 2025-02-17 | |
| Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer Binimetinib - Colorectal Cancer, Colon Cancer | Phase 2 | Completed | AIO-Studien-gGmbH | 2 | 2022-09-01 | 2025-10-01 |
| Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) combination regimen tremelimumab /durvalumab, platinum-based chemotherapy (SoC) - NSCLC Stage IV | Phase 2 | Withdrawn | AIO-Studien-gGmbH | 2022-05-20 | 2022-09-27 | |
| D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml) - Chemo-refractory Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 11 | 2022-02-17 | 2025-10-03 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study Osimertinib, Radiotherapy - NSCLC, EGFR Positive Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 42 | 2022-01-20 | 2026-01-14 |
| Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin Atezolizumab, IMM-101 - Colorectal Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 80 | 2021-12-10 | 2025-06-15 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified | Phase 1 / Phase 2 | Active not recruiting | Oncolytics Biotech | 122 | 2021-10-27 | 2026-05-19 |
| Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma non-interventional retrospective epidemiological observational study - Anemia, Iron Deficiency, Solid Tumor | Completed | AIO-Studien-gGmbH | 1053 | 2021-10-25 | 2022-02-15 | |
| Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer Bintrafusp alfa - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Terminated | AIO-Studien-gGmbH | 3 | 2021-07-08 | 2022-05-23 |
| Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients non-interventional retrospective epidemiological observational study - Secondary Immunodeficiencies (SID) | Completed | AIO-Studien-gGmbH | 1086 | 2020-01-28 | 2022-01-10 | |
| Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide Atezolizumab - SCLC, Extensive Stage | Phase 2 | Completed | AIO-Studien-gGmbH | 70 | 2020-01-06 | 2025-09-08 |
| Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. abituzumab, Placebo + Cetuximab + FOLFIRI - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | SFJ Pharmaceuticals X, LTD. | 2019-04-01 | 2020-03-18 | |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck Nivolumab and Ipilimumab, Docetaxel - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | AIO-Studien-gGmbH | 54 | 2018-07-16 | 2022-11-18 |
| Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer Pembrolizumab - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | AIO-Studien-gGmbH | 30 | 2018-06-18 | 2025-04-04 |
| Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Nivolumab, TACE - Carcinoma, Hepatocellular, Hepatic Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 49 | 2018-06-14 | 2023-07-20 |
| Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology nintedanib-nivolumab combination therapy - Adenocarcinoma of the Lung | Phase 1 / Phase 2 | Completed | AIO-Studien-gGmbH | 56 | 2018-05-25 | 2024-02-06 |
| Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 128 | 2018-05-02 | 2023-06-15 |
Showing 20 of 65. Sign in to see all of them.
Colorectal Neoplasms (10) · Neoplasm Metastasis (7) · Carcinoma, Non-Small-Cell Lung (6) · Adenocarcinoma (4) · Stomach Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Renal Cell (3) · Cholangiocarcinoma (3) · Esophageal Neoplasms (3) · Lung Neoplasms (3) · Recurrence (3) · Squamous Cell Carcinoma of Head and Neck (3) · Biliary Tract Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2)
Fluorouracil (12) · Leucovorin (8) · Nivolumab (8) · Oxaliplatin (8) · Gemcitabine (7) · Cisplatin (6) · Docetaxel (6) · Ipilimumab (5) · Panitumumab (5) · 130-nm albumin-bound paclitaxel (4) · Capecitabine (4) · durvalumab (4) · pembrolizumab (4) · Albumin-Bound Paclitaxel (3) · Cetuximab (3)
Germany (64) · Austria (4) · France (2) · Spain (2) · Belgium (1) · Czechia (1) · Italy (1) · United Kingdom (1)
Frank Griesinger, Prof. Dr. (2) · Frank Kullmann, Prof. Dr. (2) · Hartmut Link, Prof. Dr. (2) · Martin Reck, Prof. Dr. (2) · Alexander Stein, Dr. (1) · Alexander Stein, PD Dr. (1) · Alexander Stein, Prof. Dr. (1) · Amanda Tufman, Prof. Dr. (1) · Arndt Vogel, Prof. (1) · Arndt Vogel, Prof. Dr. (1) · Arndt Vogel, Prof.Dr. (1) · Deniz Gencer, Dr. (1) · Dirk Arnold, Prof. Dr. (1)
PMID 26124485, PMID 26361971, PMID 27753609, PMID 28760152, PMID 29501977, PMID 30021548, PMID 30036739, PMID 30594153, PMID 30871493, PMID 31046714, PMID 31115844, PMID 31609637, PMID 31646981, PMID 31703637, PMID 31959339, PMID 32321565, PMID 32487035, PMID 32557715, PMID 33058158, PMID 33257977, PMID 33338442, PMID 33358484, PMID 33529989, PMID 33684370, PMID 33973550, PMID 33993741, PMID 34019698, PMID 34172290, PMID 34315821, PMID 34533973, PMID 34761878, PMID 35275706, PMID 35737383, PMID 35970013, PMID 36098320, PMID 36180086, PMID 36209981, PMID 36399909, PMID 36605436, PMID 36868252, PMID 37018649, PMID 37270871, PMID 37454537, PMID 37758574, PMID 37844597, PMID 38240843, PMID 38289994, PMID 38329180, PMID 38722641, PMID 38843469
2016 (9), 2017 (6), 2014 (3), 2008 (1), 2009 (1), 2015 (1), 2018 (1), 2025 (1)